NEW YORK, May 1, 2025 /PRNewswire/ -- Ulike, a global leader in advanced at-home skincare technology, is set to launch its highly anticipated ReGlow LED Light Therapy Mask in the US on May 7, 2025. This advanced LED mask features a suite of new technology to help balance oily skin, reduce acne, even out skin tone, and restore radiance with anti-aging results seen in just four weeks.
Already popular in Asian markets, ReGlow is FDA cleared and is now set to launch in the US initially priced at $429.
Equipped with 272 high-performance LEDs, twice the number found in most standard LED masks, the ReGlow provides powerful at-home skin treatment that can both enhance radiance and smooth wrinkles while reducing redness and acne in a matter of weeks.
"Healthy, radiant skin is the foundation of a fresh, youthful look," says Ulike GM Leona Liu. "At Ulike, we're leading the way in making effective, affordable skincare treatments accessible from the comfort of home. Our new ReGlow LED Light Therapy Mask is packed with smart features — and delivers the most powerful LED treatment available today."
The Ulike ReGlow is equipped with a groundbreaking 272 professional-grade LEDs - twice the number found in most standard LED masks. This delivers faster, more powerful results that significantly reduce redness and clear acne in just 2 weeks, while smoothing wrinkles for a youthful, radiant complexion in as little as 4 weeks.[1]
ReGlow also leverages advanced 360° Mirror Reflection technology, incorporating a highly reflective inner surface that captures and redirects the LED light, amplifying light irradiance by 77.4% compared to direct exposure for even, full-face coverage and faster results.[2]
The mask's 3D ergonomic structure and woven straps offer a secure, snug fit, ensuring the device stays in place for delivering precise light therapy. It also features a 1-cm gap from the skin to evenly distribute light, minimizing heat buildup and irritation, while soft padding around the eyes provides added comfort and eye protection.
ReGlow also features 4 different therapy modes in one mask, easily adjusted in the settings for different skincare requirements.
Glow Mode for a brighter complexion and reduced melanin, revealing radiant skin in just 8 minutes.
Firm Mode smooths out fine lines and enhances skin firmness for a more youthful appearance.
Rejuvenate Mode calms redness and strengthens the skin's natural barrier, promoting healthier skin.
Clear Mode targets acne and improves overall skin health for clearer, smoother skin.
The Ulike ReGlow LED Light Therapy Mask will be available for purchase starting May 7 2025 through the Ulike website and select online retailers. More details can be found in the Ulike ReGlow press kit [link]
About Ulike
Since 2013, Ulike has harnessed the power of clinical technology to create luxurious, comfortable, and cost-effective at-home skincare solutions. The brand is known for its FDA-cleared, dermatologist-recommended IPL and LED beauty devices, designed to deliver professional-grade results from home. With over 7 million units sold across 17 countries, Ulike continues to lead in innovation, investing heavily in research to provide cutting-edge beauty-tech solutions.
Learn more at Ulike.com
PRESS CONTACT
Alessio Bradde
Global Communications & PR Senior Manager
alessiobradde@ulike.com
1 Certified by SGS (Report No. GZCPCHE23000377-01_CN & GZCPCHE23000377-04_EN) Individual results may vary.
2 Based on testing in Glow Mode and compared to direct light exposure. Individual results may vary.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Ulike Unveils the ReGlow LED Light Therapy Mask in the US for Professional-Grade Skincare at Home
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
